Computational Models Identify 41 Approved/Experimental Drugs as Putative SARS-CoV-2 Mpro Inhibitors
Background
The global SARS-CoV-2 pandemic created an urgent need for effective antiviral treatments. A key target for therapeutic intervention is the SARS-CoV-2 main protease (Mpro), also known as 3CLpro, which is essential for viral replication. Developing novel drugs from scratch is a lengthy process, making drug repurposing — identifying existing drugs that can be repurposed for new indications — a highly attractive strategy to rapidly address the public health crisis.
Study Design
Researchers developed QSAR (Quantitative Structure-Activity Relationship) models using experimental data on compounds inhibiting the SARS-CoV Mpro, which shares 96% sequence identity and 100% active site conservation with SARS-CoV-2 Mpro. These models were then employed for virtual screening of all compounds in the DrugBank database, including approved, experimental, and investigational drugs. Molecular docking and similarity search approaches were explored in parallel, but molecular docking failed to accurately differentiate between experimentally active and inactive compounds, leading to its exclusion from the primary screening strategy.
Results
The QSAR modeling approach successfully identified a significant number of potential therapeutic agents. The study recommended 41 approved, experimental, or investigational drugs as putative inhibitors of SARS-CoV-2 Mpro. These compounds represent diverse chemical structures and mechanisms, offering multiple avenues for further investigation. Among the identified candidates, 10 compounds were selected based on their feasible prices and have since been purchased, awaiting crucial experimental validation to confirm their inhibitory activity against SARS-CoV-2 Mpro in vitro. This initial computational screening provides a targeted list for accelerated drug development.
The QSAR models identified 41 drugs from DrugBank as potential SARS-CoV-2 Mpro inhibitors, with 10 selected for immediate experimental validation.
Key Findings
- QSAR models were built using inhibitory data against SARS-CoV Mpro (96% sequence identity to SARS-CoV-2 Mpro).
- Virtual screening of the DrugBank database was performed using these QSAR models.
- Molecular docking failed to discriminate between active and inactive compounds.
- 41 approved, experimental, or investigational drugs were identified as potential SARS-CoV-2 Mpro inhibitors.
- 10 compounds were purchased for subsequent experimental validation.
Why It Matters
This computational screening significantly accelerates the search for effective COVID-19 treatments by identifying existing drugs with potential antiviral activity against SARS-CoV-2 Mpro. Repurposing approved drugs could drastically reduce the time and cost associated with drug development, as their safety profiles and pharmacokinetics are already well-characterized. This approach provides a crucial starting point for experimental validation, potentially leading to a usable protocol much faster than de novo drug discovery. The identified compounds offer a diverse set of candidates for further in vitro and in vivo testing, moving closer to a clinical solution.
sars-cov-2
covid-19
drug-repurposing
computational-modeling
mpro
protease-inhibitor